Developer docs
API playgroundTry for free, no card

Search company profiles

Apex Labs

Full company profile

uuid0002ijw

Namestring
Apex Labs
Legal namestring
Apex Labs Ltd.
Websiteurl
apexlabs.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Apex Labs Ltd. is a privately held, clinical-stage pharmaceutical company headquartered in Vancouver, British Columbia, developing two patent-pending psilocybin-based drug assets for mental health indications: APEX-52, a microdose formulation intended for take-home use in moderate depression and PTSD, and APEX-90, a macrodose formulation administered in-clinic with assisted psychotherapy for severe cases. The company is currently advancing Phase 2b trials in Canada and Israel, with parallel regulatory engagement in the United States, European Union, and Australia, and has filed an IND with the FDA for its microdose candidate. Both drug candidates have reportedly achieved all endpoints without adverse events in Veteran patient populations across clinical and early access settings.

The company is Veteran-founded and positions Veterans as its primary initial patient segment, leveraging a network of Veteran-focused clinics and advocacy relationships (Wounded Warriors Canada, Heroic Hearts Project, Chronic Pain Centre of Excellence) to drive trial recruitment and, ultimately, market access. Revenue mechanics are pre-commercial: the company has no approved products or disclosed pricing, with intended future streams being pharmaceutical product sales and licensing royalties of proprietary formulations and delivery systems. Distribution is currently limited to clinical trial sites, Health Canada's Special Access Program, and a company-operated Early Access Program. Leadership combines big-pharma commercialization experience (CCO Greg Rutherford, formerly J&J, Roche, GSK, Lilly, McKesson) with clinical CNS expertise (CMO Dr. Mark Johnston).

Short descriptiontext

Apex Labs Ltd. is a Vancouver-based, Veteran-founded clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets — APEX-52 (take-home microdose) and APEX-90 (in-clinic macrodose) — for PTSD and depression, primarily targeting Veteran populations through Phase 2b trials in Canada and Israel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psilocybin therapeutics, clinical stage pharmaceuticals, mental health drug development, psychedelic drug delivery, PTSD depression treatment
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Psilocybin-based Psychedelic Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Once regulatory approval is obtained, Apex Labs plans to commercialize its psilocybin-based drug products (APEX-52 and APEX-90) for treatment of PTSD and depression. The company is in clinical development stage with no current commercial revenue.

apexlabs.com
2Licensing Royalties
TypeLicensing Royalties
Description

Potential licensing of proprietary drug formulations and delivery systems to pharmaceutical partners upon regulatory approval in various jurisdictions.

apexlabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1APEX-52
Description

Microdose formulation designed for take-home use targeting moderate depression and PTSD.

apexlabs.com
+1 more record
Core offering1 text field

Apex Labs is a clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets for the treatment of PTSD and depression. APEX-52 is a microdose formulation designed for take-home use targeting moderate cases, while APEX-90 is a macrodose formulation intended for in-clinic dosing with assisted psychotherapy targeting severe cases. Both candidates are being advanced through Phase 2b clinical trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Both drug candidates achieved all endpoints without adverse events in clinical and early access settings
+1 more record
Product overview1 text field

Apex Labs is a patient-driven pharmaceutical company developing two distinct, patent-pending psilocybin-based drug assets for mental health treatment: APEX-52 (Microdose) and APEX-90 (Macrodose). APEX-52 is a take-home microdose formulation targeting moderate depression and PTSD, while APEX-90 is an in-clinic macrodose therapy with assisted psychotherapy for severe cases. Both drug candidates have achieved all clinical endpoints without adverse events in Veteran patient populations. The company is advancing Phase 2b trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia toward global market access.

Product and service2 records
1APEX-52 (Microdose)
CategoryPsilocybin-based Pharmaceutical (Microdose)
Description

A patent-pending psilocybin microdose formulation designed for take-home use, targeting moderate depression and PTSD. Optimized for patients who can self-administer outside of clinical settings. Being advanced through clinical development with regulatory engagement in Canada, US, Israel, EU, and Australia.

2APEX-90 (Macrodose)
CategoryPsilocybin-based Pharmaceutical (Macrodose)
Description

A patent-pending psilocybin macrodose formulation intended for in-clinic dosing with assisted psychotherapy, targeting severe cases of depression and PTSD. Administered under medical supervision. Currently being dosed in Phase 2b clinical trials in Canada and Israel and through the company's Early Access Program for qualified patients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeOthers
Description

Arron Victory, Chief Strategy Officer and co-Founder, serves as an Ambassador for this Veteran advocacy group that provides support to Veterans and their families.

Strategic tierMinorTypeOthers
Description

Arron Victory serves as Board Member of this charity that provides access to psychedelic therapies for Veterans.

Strategic tierMinorTypeOthers
Description

Arron Victory serves as Advisory Board Member of this research centre improving understanding of Veteran-specific chronic pain and management strategies.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

IP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy in the psychedelics space.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

IP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Compass Pathways is developing psilocybin therapy (COMP360) for treatment-resistant depression and is the most advanced publicly listed pure-play psilocybin developer. Direct competitor to Apex Labs in psychedelic-based mental health therapeutics with a similar mechanism and clinical development approach.

2Mydecine Innovations Group
TypeEmerging player
Description

Mydecine is a psychedelic medicine company developing psilocybin and other natural-sourced compounds for mental health indications. Early-stage peer with similar psychedelic drug development focus but smaller and earlier-stage clinical programs.

3ATAI Life Sciences
TypeBroad incumbent
Description

ATAI is a clinical-stage biopharmaceutical company developing a portfolio of psychedelic and non-psychedelic mental health therapies, including a controlling stake in Compass Pathways. Broader platform incumbent in psychedelic therapeutics with materially greater capital and pipeline depth.

4MindMed
TypeDirect peer
Description

MindMed is a clinical-stage psychedelic medicine biotech developing LSD and psilocybin-based therapies for anxiety, depression, and ADHD. Direct competitor to Apex Labs in the psychedelic pharmaceutical space, with publicly listed status and broader capital access.

TypeRegional player
Description

Numinus is a Canadian-based mental health company operating psychedelic-assisted therapy clinics and a research division. Regional peer in the same Canadian market as Apex Labs, with overlapping interest in psilocybin clinical research and clinic-based service delivery.

TypeDirect peer
Description

Small Pharma is developing SPL026 (DMT) and other psychedelic-based therapies for depression, with clinical programs in the UK. Direct peer focused on psychedelic pharmaceutical drug development, similar size and stage to Apex Labs.

TypeDirect peer
Description

Cybin is developing psilocybin and deuterated psilocybin analogs (CYB003) for depression and other mental health indications. Direct peer in psychedelic drug development with similar indications and a broader deuterated-psilocybin patent strategy.

8Field Trip Health (Delic Corp)
TypeDirect peer
Description

Formerly Field Trip Health, Delic operates psychedelic therapy clinics and develops related pharmaceutical assets. Comparable to Apex Labs in the psychedelic mental health space, though more focused on clinic delivery and ketamine-based services.

TypeEmerging player
Description

Clearmind is a psychedelic pharmaceutical company developing novel compounds (including non-hallucinogenic options) for addiction and mental health disorders. Emerging peer with partial overlap in psychedelic-based mental health treatment development.

TypeDirect peer
Description

GH Research is developing psilocybin (GH001) for treatment-resistant depression, with active Phase 2b/3 trials in Europe and the US. Closely comparable to Apex Labs' APEX-90 program in mechanism, indication, and clinical development stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apex Labs

Psilocybin-based Psychedelic Pharmaceuticalsapexlabs.com

Apex Labs Ltd. is a Vancouver-based, Veteran-founded clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets — APEX-52 (take-home microdose) and APEX-90 (in-clinic macrodose) — for PTSD and depression, primarily targeting Veteran populations through Phase 2b trials in Canada and Israel.

What Apex Labs does

Apex Labs Ltd. is a privately held, clinical-stage pharmaceutical company headquartered in Vancouver, British Columbia, developing two patent-pending psilocybin-based drug assets for mental health indications: APEX-52, a microdose formulation intended for take-home use in moderate depression and PTSD, and APEX-90, a macrodose formulation administered in-clinic with assisted psychotherapy for severe cases. The company is currently advancing Phase 2b trials in Canada and Israel, with parallel regulatory engagement in the United States, European Union, and Australia, and has filed an IND with the FDA for its microdose candidate. Both drug candidates have reportedly achieved all endpoints without adverse events in Veteran patient populations across clinical and early access settings.

The company is Veteran-founded and positions Veterans as its primary initial patient segment, leveraging a network of Veteran-focused clinics and advocacy relationships (Wounded Warriors Canada, Heroic Hearts Project, Chronic Pain Centre of Excellence) to drive trial recruitment and, ultimately, market access. Revenue mechanics are pre-commercial: the company has no approved products or disclosed pricing, with intended future streams being pharmaceutical product sales and licensing royalties of proprietary formulations and delivery systems. Distribution is currently limited to clinical trial sites, Health Canada's Special Access Program, and a company-operated Early Access Program. Leadership combines big-pharma commercialization experience (CCO Greg Rutherford, formerly J&J, Roche, GSK, Lilly, McKesson) with clinical CNS expertise (CMO Dr. Mark Johnston).

Apex Labs firmographics

Firmographics
Name
Apex Labs
Legal name
Apex Labs Ltd.
Website
https://apexlabs.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Apex Labs Ltd. is a Vancouver-based, Veteran-founded clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets — APEX-52 (take-home microdose) and APEX-90 (in-clinic macrodose) — for PTSD and depression, primarily targeting Veteran populations through Phase 2b trials in Canada and Israel.
Ownership category
akta.pro rank

Where Apex Labs is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Apex Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Once regulatory approval is obtained, Apex Labs plans to commercialize its psilocybin-based drug products (APEX-52 and APEX-90) for treatment of PTSD and depression. The company is in clinical development stage with no current commercial revenue.
  2. Licensing Royalties: Potential licensing of proprietary drug formulations and delivery systems to pharmaceutical partners upon regulatory approval in various jurisdictions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Apex Labs product offering

Product offering

Core offering

Apex Labs is a clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets for the treatment of PTSD and depression. APEX-52 is a microdose formulation designed for take-home use targeting moderate cases, while APEX-90 is a macrodose formulation intended for in-clinic dosing with assisted psychotherapy targeting severe cases. Both candidates are being advanced through Phase 2b clinical trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia.

Product overview

Apex Labs is a patient-driven pharmaceutical company developing two distinct, patent-pending psilocybin-based drug assets for mental health treatment: APEX-52 (Microdose) and APEX-90 (Macrodose). APEX-52 is a take-home microdose formulation targeting moderate depression and PTSD, while APEX-90 is an in-clinic macrodose therapy with assisted psychotherapy for severe cases. Both drug candidates have achieved all clinical endpoints without adverse events in Veteran patient populations. The company is advancing Phase 2b trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia toward global market access.

Differentiator

Problem solved

Functional benefit

Brands

  • APEX-52: Microdose formulation designed for take-home use targeting moderate depression and PTSD.
  • APEX-90

Products and services

  • APEX-52 (Microdose) A patent-pending psilocybin microdose formulation designed for take-home use, targeting moderate depression and PTSD. Optimized for patients who can self-administer outside of clinical settings. Being advanced through clinical development with regulatory engagement in Canada, US, Israel, EU, and Australia.
  • APEX-90 (Macrodose) A patent-pending psilocybin macrodose formulation intended for in-clinic dosing with assisted psychotherapy, targeting severe cases of depression and PTSD. Administered under medical supervision. Currently being dosed in Phase 2b clinical trials in Canada and Israel and through the company's Early Access Program for qualified patients.

Quantifiable outcome

  • Both drug candidates achieved all endpoints without adverse events in clinical and early access settings
  • +1 more outcomes

Companies that use Apex Labs

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Apex Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Apex Labs partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor.

  • Wounded Warriors CanadaminorOthersArron Victory, Chief Strategy Officer and co-Founder, serves as an Ambassador for this Veteran advocacy group that provides support to Veterans and their families.
  • Heroic Hearts ProjectminorOthersArron Victory serves as Board Member of this charity that provides access to psychedelic therapies for Veterans.
  • Chronic Pain Centre of ExcellenceminorOthersArron Victory serves as Advisory Board Member of this research centre improving understanding of Veteran-specific chronic pain and management strategies.
  • Cooley LLPminorImplementation/ SI/ Consulting PartnerIP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy in the psychedelics space.
  • BLG (Borden Ladner Gervais)minorImplementation/ SI/ Consulting PartnerIP/patent counsel engaged by Apex Labs for intellectual property development and patent protection strategy.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Apex Labs competitors and assessment

Company assessment

Direct peers

  • Compass Pathways: Compass Pathways is developing psilocybin therapy (COMP360) for treatment-resistant depression and is the most advanced publicly listed pure-play psilocybin developer. Direct competitor to Apex Labs in psychedelic-based mental health therapeutics with a similar mechanism and clinical development approach.
  • MindMed: MindMed is a clinical-stage psychedelic medicine biotech developing LSD and psilocybin-based therapies for anxiety, depression, and ADHD. Direct competitor to Apex Labs in the psychedelic pharmaceutical space, with publicly listed status and broader capital access.
  • Small Pharma: Small Pharma is developing SPL026 (DMT) and other psychedelic-based therapies for depression, with clinical programs in the UK. Direct peer focused on psychedelic pharmaceutical drug development, similar size and stage to Apex Labs.
  • Cybin Inc. Cybin is developing psilocybin and deuterated psilocybin analogs (CYB003) for depression and other mental health indications. Direct peer in psychedelic drug development with similar indications and a broader deuterated-psilocybin patent strategy.
  • Field Trip Health (Delic Corp): Formerly Field Trip Health, Delic operates psychedelic therapy clinics and develops related pharmaceutical assets. Comparable to Apex Labs in the psychedelic mental health space, though more focused on clinic delivery and ketamine-based services.
  • GH Research: GH Research is developing psilocybin (GH001) for treatment-resistant depression, with active Phase 2b/3 trials in Europe and the US. Closely comparable to Apex Labs' APEX-90 program in mechanism, indication, and clinical development stage.

Emerging players

  • Mydecine Innovations Group: Mydecine is a psychedelic medicine company developing psilocybin and other natural-sourced compounds for mental health indications. Early-stage peer with similar psychedelic drug development focus but smaller and earlier-stage clinical programs.
  • Clearmind Medicine: Clearmind is a psychedelic pharmaceutical company developing novel compounds (including non-hallucinogenic options) for addiction and mental health disorders. Emerging peer with partial overlap in psychedelic-based mental health treatment development.

Broad incumbents

  • ATAI Life Sciences: ATAI is a clinical-stage biopharmaceutical company developing a portfolio of psychedelic and non-psychedelic mental health therapies, including a controlling stake in Compass Pathways. Broader platform incumbent in psychedelic therapeutics with materially greater capital and pipeline depth.

Regional players

  • Numinus Wellness: Numinus is a Canadian-based mental health company operating psychedelic-assisted therapy clinics and a research division. Regional peer in the same Canadian market as Apex Labs, with overlapping interest in psilocybin clinical research and clinic-based service delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Apex Labs social profiles

Digital presence

Apex Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apex Labs leadership team

Management profile

Number of profiles

Profiles11 records

Apex Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apex Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apex Labs

What does Apex Labs do?

Apex Labs is a clinical-stage pharmaceutical company developing two patent-pending psilocybin-based drug assets for the treatment of PTSD and depression. APEX-52 is a microdose formulation designed for take-home use targeting moderate cases, while APEX-90 is a macrodose formulation intended for in-clinic dosing with assisted psychotherapy targeting severe cases. Both candidates are being advanced through Phase 2b clinical trials in Canada and Israel, with regulatory engagement in the US, EU, and Australia.

Is Apex Labs a public or private company?

Apex Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Apex Labs founded?

Apex Labs was founded in 2021. It employs 11 to 50 people.

Where is Apex Labs based?

Apex Labs is headquartered in Vancouver, Canada, in the North America region.

How does Apex Labs make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.

Who are Apex Labs's main competitors?

Direct peers on record are Compass Pathways, MindMed, Small Pharma, Cybin Inc., Field Trip Health (Delic Corp) and GH Research. Emerging players are Mydecine Innovations Group and Clearmind Medicine. ATAI Life Sciences is listed as a broad incumbent. Numinus Wellness is listed as a regional player.

Does Apex Labs have an API?

No public API is recorded for Apex Labs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireApex Labs Granted Dealer's Licence by Health CanadaApex Labs Ltd. has been granted a Dealer's Licence by Health Canada, authorizing the company to sell its psilocybin drug products under the Special Access Program. This approval simplifies the supply chain for APEX-52 and APEX-90, allowing direct sales for investigator-led clinical trials and access for patients with unmet mental health needs. The licence was issued within four months of application without observations, facilitating broader distribution to Veteran patients and Canadians.PR NewswireCanadian Veteran Dosed with First Cycle of APEX-90 Macrodose Psilocybin in Apex Labs' Early Access Program.Apex Labs Ltd. has launched its multi-dose Early Access Program for APEX-90 macrodose psilocybin and successfully dosed the first Canadian veteran patient under this program, with the treatment administered in-clinic with assisted psychotherapy. The EAP supports physicians accessing psilocybin through Health Canada's Special Access Program and is specifically designed for Canadian Armed Forces and RCMP Veterans suffering from moderate or severe depression and PTSD. The program is aligned with the ongoing SUMMIT-90 phase 2b clinical trial and is expected to expand significantly in 2024 to address the critical unmet need in mental health treatment for veterans.PR NewswireApex Labs announces the appointment of Chief Medical Officer & Chief Commercial OfficerApex Labs Ltd. announced the appointment of psychiatrist Dr. Mark Johnston as Chief Medical Officer and Greg Rutherford as Chief Commercial Officer, both bringing extensive clinical trial and pharmaceutical commercialization experience to the company. The additions are intended to accelerate the company's psilocybin-based drug development programs, including Phase 2b clinical trials PATHFINDER-52 and SUMMIT-90 for treating depression and anxiety in PTSD patients. The company, which focuses on clinically proven psilocybin treatments with Veterans as an initial patient base, noted that the new executives will support its goal of entering the US market and advancing multiple clinical programs through 2023/2024.PR NewswireApex Labs Receives Approval for US-Based Secondary GMP Psilocybin Supplier by Health CanadaApex Labs Ltd. received Health Canada approval for a secondary US-based GMP psilocybin Active Pharmaceutical Ingredient supplier, complementing its existing Canadian supplier and establishing cross-border supply chain stability. The company is now shipping drug products across the Canadian-US border with permit approvals from Health Canada, the Drug Enforcement Administration, and US customs. Apex Labs plans to leverage its Health Canada regulatory submissions to file an Investigational New Drug application with the FDA in 2023, supporting its planned clinical programs and Early Access Program in both markets.PR NewswireApex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical TrialApex Labs Ltd. announced the completion of the first-ever take home microdose psilocybin clinical trial, STEP-52, meeting all endpoints over a two-month period with no adverse events in patients diagnosed with PTSD-related depression within the Veteran community. The study also demonstrated stable symptoms when patients transitioned from illicit unregulated psilocybin to regulated APEX-52 synthetic psilocybin manufactured under GMP standards. The company has also received Health Canada approval for a 294-participant phase 2b trial, PATHFINDER-52, described as the largest take home microdose clinical trial approved to date.PR NewswireApex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical TrialApex Labs Ltd. received approval from Health Canada via a No Objection Letter on January 5th, 2023, to begin APEX-002-A01-03, a randomized, double-blind, placebo-controlled phase 2b clinical trial evaluating APEX-52, a microdose synthetic psilocybin drug product for treating depression and anxiety in adults with PTSD. The trial will recruit 294 patients across sites in Ontario and Atlantic Canada, making it the world's largest take-home psilocybin clinical trial approved to date, with recruitment beginning in the first half of 2023 and the study spanning three months.PR NewswireApex Labs Doses First Patient in Take Home Psilocybin Clinical TrialApex Labs Ltd., a Canadian pharmaceutical company, has commenced patient dosing in its phase 2b take-home multi-dose psilocybin clinical trial (APEX-002-A01-02), evaluating APEX-52 for treating depression and anxiety in veterans diagnosed with PTSD. A Canadian veteran took the first dose of APEX-52, a GMP-manufactured microdose psilocybin drug product, marking the first pharmaceutical-grade at-home psilocybin dosing study in North America. The trial is designed to evaluate the safety and efficacy of transitioning patients from unregulated psilocybin to the regulated synthetic formulation, with results expected to inform future phase 3 clinical study design.PR NewswireApex Labs Granted Approval for North America's First Take Home Psilocybin Clinical TrialApex Labs Ltd. received approval from Health Canada on October 24, 2022, to conduct North America's first take-home multi-dose psilocybin clinical trial, APEX-002-A01-02, evaluating APEX-52 for treating depression in Veterans with PTSD. The trial represents a significant regulatory milestone, enabling patients to self-administer the GMP-manufactured, orally delivered psilocybin drug product in their own homes. The company's CEO stated this approval addresses a gap where Veterans are currently self-medicating with unregulated psilocybin products, and that the company aims to expand access to pharmaceutical-grade alternatives through regulated channels.